Macrophage-Like Cells Emerge as Dynamic Biomarker for Tracking Diabetic Macular Edema Treatment Response
核心洞察
A six-month retrospective study of 86 eyes with type 2 diabetes found that macrophage-like cell (MLC) counts rise significantly with worsening diabetic retinopathy (搜索), from 165.06 in non-retinopathy eyes to 254.12 in untreated DME.
Anti-VEGF (搜索) therapy reduced MLC counts from 383.75 to 207.00 alongside improvements in central subfield thickness and visual acuity, while dexamethasone implants similarly lowered MLC density from 8.37 to 5.20 cells/mm².
MLC density demonstrated a strong positive correlation with glycosylated hemoglobin levels, best-corrected visual acuity, and foveal thickness, supporting its reliability as an indicator of active disease.
A new study from Sankara Nethralaya (搜索) has demonstrated that macrophage-like cells (MLCs) at the vitreoretinal interface can serve as a dynamic, non-invasive biomarker for tracking disease progression and treatment response in diabetic macular edema (搜索) (DME). The research, published in the Indian Journal of Ophthalmology, provides the first longitudinal evidence linking changes in MLC density to standard therapeutic outcomes in patients with varying stages of diabetic retinopathy (搜索).
Led by Dr. Sundaramoorthy Sathishkumar and Dr. Dhanashree Ratra, the six-month, retrospective, cross-sectional study evaluated 86 eyes with type 2 diabetes using optical coherence tomography angiography (OCTA). Patients were stratified into four groups: no retinopathy, untreated DME, anti-VEGF (搜索)-treated DME, and dexamethasone-treated DME. Individuals with proliferative disease, prior ocular surgeries, or confounding macular conditions were excluded from the analysis.
MLC Counts Reflect Inflammatory Disease Progression
The study established a clear gradient of MLC elevation corresponding to disease severity. Baseline MLC counts rose significantly from 165.06 in eyes without diabetic retinopathy (搜索) to 254.12 in eyes with untreated DME, directly reflecting the inflammatory progression underlying the condition. This finding reinforces the role of local immune activation in DME pathogenesis and positions MLCs as quantifiable markers of disease activity.
Anti-VEGF (搜索) Therapy Drives Substantial MLC Reduction
Among eyes receiving anti-VEGF (搜索) injections, investigators documented a substantial drop in MLC counts from 383.75 to 207.00 following treatment. This reduction was accompanied by improvements in central subfield thickness (CST), which decreased from 398.70 µm to 342.39 µm, and marked gains in best-corrected visual acuity (BCVA). The parallel improvements across cellular, structural, and functional parameters underscore the utility of MLC monitoring as a comprehensive treatment response indicator.
Dexamethasone Implants Show Comparable Anti-Inflammatory Effects
Steroidal implant therapy produced similarly compelling results. MLC density declined from 8.37 to 5.20 cells/mm², while macular thickness decreased from 581.63 µm to 417.71 µm. The comparable performance of dexamethasone in mitigating local inflammation suggests that MLC dynamics may serve as a universal biomarker across different therapeutic classes, regardless of mechanism of action.
Biomarker Validation Through Clinical Correlations
The researchers confirmed a strong positive association between MLC density and key clinical parameters, including glycosylated hemoglobin (HbA1c) levels, BCVA, and foveal thickness. These correlations establish the reliability of MLCs as indicators of active disease and validate their potential integration into routine clinical decision-making.
Overall, the results demonstrate that MLCs actively increase with worsening diabetic retinopathy (搜索) and decrease by an average of over 139 cells following effective therapeutic intervention. This notable reduction directly correlates with both structural and functional vision improvements.
Clinical Implications and Future Directions
Incorporating the non-invasive observation of these motile immune cells into routine OCTA imaging evaluations may provide clinicians with a supplemental tool to anticipate and track early patient responses to pharmacologic therapies. The authors note that manual image segmentation and the inherent motility of MLCs present minor observational variables. Further exploration of specific morphological changes and migration patterns in larger longitudinal cohorts could refine and enrich the diagnostic value of this emerging biomarker.